In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting ...
Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...
Parent Project Muscular Dystrophy (PPMD), the largest U.S. non-profit leading Duchenne and Becker muscular dystrophy care, research, and advocacy efforts, and MyoGene Bio (MyoGene) are excited to ...
Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...
Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons ...
In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...
Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...
News-Medical.Net on MSN
Researchers develop a versatile tool for controlling gene activity
Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback